Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis

Open access
Elmariah, Sammy, Mauri, Laura, Doros, Gheorghe, Galper, Benjamin Z, O'Neill, Kelly E, Steg, Philippe Gabriel, Kereiakes, Dean J, Yeh, Robert W · 2015 · The Lancet

Abstract

Background Treatment with the combination of aspirin and a P2Y12 inhibitor is commonly employed in a number of cardiovascular conditions. The overall impact of such treatment on all-cause mortality is unknown. In the Dual Antiplatelet Therapy (DAPT) Study, an international multicenter randomized placebo-controlled trial comparing 30 versus 12 months of dual antiplatelet therapy after coronary stenting, continuation of DAPT beyond 12 months was associated with an increase in mortality at trial completion, largely attributable to an increase in non-cardiovascular death. Given the potential public health importance of this, we performed a meta-analysis of all randomized, controlled trials of DAPT duration across a wide array of cardiovascular conditions to evaluate the impact of extended duration DAPT on mortality. Methods A systematic literature search of MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) database was performed to identify randomized controlled trials evaluating the impact of extended duration versus no or short-duration DAPT. Study results were pooled using a hierarchical Bayesian random-effects model. The primary outcomes examined were hazard ratios comparing rates of all-cause, cardiovascular, and non-cardiovascular death. Findings Including the DAPT Study, we identified 14 eligible trials that randomized 69,644 subjects to different durations of DAPT. Compared with aspirin alone or short-duration DAPT (≤ 6 months), continued DAPT was not associated with a difference in all-cause mortality (hazard ratio [HR] 1·05; 95% credible interval [CrI], 0·96–1·19). Similarly, cardiovascular (HR 1·01; 95% CrI, 0·93–1·12) and non-cardiovascular mortality (HR 1·04; 95% CrI, 0·90–1·26) were no different with extended duration vs. short duration DAPT or aspirin alone. Interpretation In a meta-analysis of 14 trials, extended duration DAPT was not associated with a difference in the risk of all-cause, cardiovascular, or non-cardiovascular death compared with aspirin alone or short duration DAPT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)62052-3

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 168

Metadata

Authors
Elmariah, S., Mauri, L., Doros, G., Galper, B. Z., O'Neill, K. E., Steg, P. G., Kereiakes, D. J., & Yeh, R. W.
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-02
Volume
385
Issue
9970
Pages
792-798
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2136520492
Cited by
168
References
6
FWCI
6.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(14)62052-3
The paper
Elmariah, S., Mauri, L., Doros, G., Galper, B. Z., O'Neill, K. E., Steg, P. G., Kereiakes, D. J., & Yeh, R. W. (2015). Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(14)62052-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.